Cero Therapeutics Hldgs Inc.
13F holders, Q2 2024 (June 30)15holders +6
8new positions
2sold out
$0.29avg. 13F price*
At the end of Q2 2024, 15 institutions reported holding Cero Therapeutics Hldgs Inc. in their 13F filings, up 6 from Q1 2024. 8 opened new positions and 2 sold out. The largest holders were ARCH Venture Management, LLC ($432K), Arena Investors LP ($59K) and Avantax Planning Partners, Inc. ($24K).
- Company
- Cero Therapeutics Hldgs Inc.
- CUSIP
- 71902K105
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $96K |
| Exits | 2 | $233K |
All 13F filers, Q1 2024 → Q2 2024: 443,733 shares bought and 165,249 shares sold, net +278,484 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| ARCH Venture Management, LLC | 0.16% | No change | 1,444,296 | $432K |
| Arena Investors LP | 3.13% | New | 198,566 | $59K |
| Avantax Planning Partners, Inc. | 0.00% | New | 80,000 | $24K |
| Geode Capital Management, LLC | 0.00% | Add +354.7% | 48,142 | $14K |
| Jane Street Group, LLC | 0.00% | Add +20.8% | 32,037 | $10K |
| Two Sigma Investments, LP | 0.00% | New | 18,096 | $5K |
| Corient Private Wealth LP | 0.00% | New | 14,999 | $4K |
| Birchview Capital, LP | 0.00% | No change | 12,972 | $4K |
| HRT Financial LP | 0.00% | New | 11,935 | $3K |
| FNY Investment Advisers, LLC | 0.00% | Reduce -50.0% | 5,250 | $1K |
| Osaic Holdings, Inc. | 0.00% | New | 400 | $120 |
| Pineridge Advisors LLC | 0.00% | No change | 300 | $90 |
| Bank of America Corp. | 0.00% | New | 68 | $20 |
| JPMorgan Chase & Co. | 0.00% | No change | 2 | $1 |
| Fifth Lane Capital, LP | 0.00% | New | 76,593 | $0 |
"% of holder's portfolio" is CERO THERAPEUTICS HLDGS INC's weight in each manager's 13F, not the share of Cero Therapeutics Hldgs Inc. the manager owns.